OP2LYSIS DEVELOPMENT
0769.816.843 · rovalta.com · 22/09/2026
OP2LYSIS DEVELOPMENT
Company — Opening of bankruptcy.
Overview
What does OP2LYSIS DEVELOPMENT do?
OP2LYSIS DEVELOPMENT is a Public limited company incorporated in 2021. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 1,0 ETP workers (FTE).
4000 Liège · WallonieSee on map
Trend over 3 financial years
| 2024 | 2023 | 2022 | |||
|---|---|---|---|---|---|
| Income statement | |||||
| Gross margin | -20,4 k € | +29.4% | -28,8 k € | -132% | 88,8 k € |
| EBITDA | -96,4 k € | +61.4% | -249,8 k € | -42.1% | -175,8 k € |
| Operating result | -96,4 k € | +61.4% | -249,8 k € | -41.1% | -177,1 k € |
| Net result | -116,2 k € | +47.2% | -220 k € | -50.5% | -146,2 k € |
| Balance sheet | |||||
| Equity | 1,8 M € | -2.0% | 1,9 M € | +29.4% | 1,4 M € |
| Total assets | 3 M € | -4.4% | 3,2 M € | +9.0% | 2,9 M € |
| Cash | 41,4 k € | -92.6% | 558,9 k € | +308% | 136,9 k € |
| Debts | 1,2 M € | -7.8% | 1,3 M € | -10.8% | 1,5 M € |
| Other | |||||
| Workforce | 1,0 ETP | -47.4% | 1,9 ETP | +11.8% | 1,7 ETP |
Board of directors
Seen on filing of 31/12/2024 · 1 active
Active mandates
Other companies at this address
| Company | CBE no. |
|---|---|
Abscint● Active | 0749.828.410 |
AMPACIMON● Active | 0827.990.317 |
Amyl Therapeutics● Active | 0758.775.372 |
BECARV● Bankrupt | 0840.777.885 |
BE.SPINE● Active | 1013.110.857 |
CEFALY Technology● Active | 0870.578.661 |
DERMAX● Active | 0667.730.677 |
DIANOSIC● Active | 1034.558.646 |
DW Cefaly Holding● Active | 0725.837.241 |
| 1023.778.481 | |
EXO Biologics● Active | 0732.982.379 |
ExoXpert● Active | 1003.807.666 |
Hirundo Biosciences● Active | 0681.855.065 |
HolyFox Invest● Active | 1010.693.181 |
Hyloris● Active | 0669.738.676 |
Hyloris Developments● Active | 0542.737.368 |
Hyloris Pharmaceuticals● Active | 0674.494.151 |
Hyloris Therapeutics● Active | 1025.029.385 |
LEGIAPARK● Active | 0728.589.170 |
MAN & SCIENCE● Active | 0837.403.770 |
Financials
Full financial information
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/06/2021 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 |
| Length of the financial year | 12 months | 12 months | 19 months |
| Filing date | 18/06/2025 | 13/06/2024 | 28/07/2023 |
| General meeting | 05/06/2025 | 06/06/2024 | 22/06/2023 |
| Currency of the financial year | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
3 filings with the NBB
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Seen on filing of 31/12/2024 · 1 active
Active mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
- Capital / shares17/01/2024CAPITAL, ACTIONS
- Registered office29/11/2022STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - SIEGE SOCIAL - CAPITAL, ACTIONS
- Mandates21/03/2022DEMISSIONS, NOMINATIONS
- Other21/06/2021RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
Source: Belgian Official Gazette
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 2024-116,2 k €↑
- 2023Annual accounts 2023-220 k €↓
- 2022Annual accounts 2022-146,2 k €
- 17/06/2021IncorporationPublic limited company